<HashMap><database>biostudies-literature</database><scores/><additional><submitter>DiGiandomenico S</submitter><funding>U.S. Department of Health and Human Services</funding><funding>National Heart, Lung, and Blood Institute</funding><funding>NHLBI NIH HHS</funding><funding>Midwest Athletes Against Childhood Cancer</funding><pagination>131-138</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7790985</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation resulted in many patients receiving a different type 2 diagnosis. Some genetic variants were particularly likely to move type 2 subcategories. ABSTRACT: Introduction Type 2 von Willebrand disease (VWD) refers to patients with a qualitative defect in von Willebrand factor. Accurate diagnosis of type 2 VWD subtypes can be challenging. Aim of the study To compare the historical diagnosis of type 2 VWD with current laboratory testing. Methods Subjects were enrolled in the Zimmerman Program either because of a preexisting diagnosis of VWD (retrospective cohort) or from evaluation for bleeding symptoms or suspected VWD (prospective cohort). Origi</pubmed_abstract><journal>Journal of thrombosis and haemostasis : JTH</journal><pubmed_title>Laboratory variability in the diagnosis of type 2 VWD variants.</pubmed_title><pmcid>PMC7790985</pmcid><funding_grant_id>HL136430</funding_grant_id><funding_grant_id>R01 HL112614</funding_grant_id><funding_grant_id>HL081588</funding_grant_id><funding_grant_id>HL126810</funding_grant_id><funding_grant_id>R01 HL136430</funding_grant_id><funding_grant_id>R01 HL126810</funding_grant_id><funding_grant_id>HL144457</funding_grant_id><funding_grant_id>P01 HL144457</funding_grant_id><funding_grant_id>P01 HL081588</funding_grant_id><funding_grant_id>HL112614</funding_grant_id><funding_grant_id>R01 HL139847</funding_grant_id><pubmed_authors>Ragni M</pubmed_authors><pubmed_authors>Konkle B</pubmed_authors><pubmed_authors>Brown D</pubmed_authors><pubmed_authors>Abshire T</pubmed_authors><pubmed_authors>Gill J</pubmed_authors><pubmed_authors>Tarantino M</pubmed_authors><pubmed_authors>Zimmerman Program Investigators</pubmed_authors><pubmed_authors>Christopherson PA</pubmed_authors><pubmed_authors>James P</pubmed_authors><pubmed_authors>Lillicrap D</pubmed_authors><pubmed_authors>Werner E</pubmed_authors><pubmed_authors>DiGiandomenico S</pubmed_authors><pubmed_authors>Abshire TC</pubmed_authors><pubmed_authors>Shapiro A</pubmed_authors><pubmed_authors>Kulkarni R</pubmed_authors><pubmed_authors>Paola JD</pubmed_authors><pubmed_authors>Gruppo R</pubmed_authors><pubmed_authors>Journeycake J</pubmed_authors><pubmed_authors>Sharathkumar A</pubmed_authors><pubmed_authors>Hord J</pubmed_authors><pubmed_authors>DiMichele D</pubmed_authors><pubmed_authors>Singer T</pubmed_authors><pubmed_authors>Shafer F</pubmed_authors><pubmed_authors>Montgomery RR</pubmed_authors><pubmed_authors>Valentino L</pubmed_authors><pubmed_authors>Bedros A</pubmed_authors><pubmed_authors>Mathias L</pubmed_authors><pubmed_authors>Paidas M</pubmed_authors><pubmed_authors>Dunn A</pubmed_authors><pubmed_authors>Kerlin B</pubmed_authors><pubmed_authors>Diamond C</pubmed_authors><pubmed_authors>Hoots WK</pubmed_authors><pubmed_authors>Manco-Johnson M</pubmed_authors><pubmed_authors>Flood VH</pubmed_authors><pubmed_authors>Stein D</pubmed_authors><pubmed_authors>Rajpurkar M</pubmed_authors><pubmed_authors>Leissinger C</pubmed_authors><pubmed_authors>Lentz S</pubmed_authors><pubmed_authors>Cuker A</pubmed_authors><pubmed_authors>Boggio L</pubmed_authors><pubmed_authors>Neff A</pubmed_authors><pubmed_authors>Bennett C</pubmed_authors><pubmed_authors>Haberichter SL</pubmed_authors><pubmed_authors>Matsunaga A</pubmed_authors><pubmed_authors>Lusher J</pubmed_authors><pubmed_authors>Paroskie A</pubmed_authors><pubmed_authors>Kouides P</pubmed_authors><pubmed_authors>Ma A</pubmed_authors><pubmed_authors>Cohen A</pubmed_authors><pubmed_authors>Mahoney D</pubmed_authors><pubmed_authors>Giardina P</pubmed_authors><pubmed_authors>Roberts J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Laboratory variability in the diagnosis of type 2 VWD variants.</name><description>Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation resulted in many patients receiving a different type 2 diagnosis. Some genetic variants were particularly likely to move type 2 subcategories. ABSTRACT: Introduction Type 2 von Willebrand disease (VWD) refers to patients with a qualitative defect in von Willebrand factor. Accurate diagnosis of type 2 VWD subtypes can be challenging. Aim of the study To compare the historical diagnosis of type 2 VWD with current laboratory testing. Methods Subjects were enrolled in the Zimmerman Program either because of a preexisting diagnosis of VWD (retrospective cohort) or from evaluation for bleeding symptoms or suspected VWD (prospective cohort). Origi</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jan</publication><modification>2025-04-21T21:35:10.132Z</modification><creation>2022-02-11T13:38:01.34Z</creation></dates><accession>S-EPMC7790985</accession><cross_references><pubmed>33049112</pubmed><doi>10.1111/jth.15129</doi></cross_references></HashMap>